A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Conditions

Coronary Artery Disease

What is the purpose of this trial?

The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).



Participation Guidelines

Age:
18 Years - N/A
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Lantheus Medical Imaging
Dates:
June 2011
Last Updated:
August 14, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01347710